» Articles » PMID: 7517170

Toxicity of Ifosfamide, Cyclophosphamide and Their Metabolites in Renal Tubular Cells in Culture

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 1994 Apr 1
PMID 7517170
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Ifosfamide (IF) and cyclophosphamide (CP) are highly effective alkylating cytostatic drugs. IF and CP have to be activated through a metabolic step in vivo; numerous metabolites are known. While both IF and its structural isomer CP have severe urotoxic side effects, only IF is also a nephrotoxic drug, causing tubular damage resulting in Fanconi syndrome in some cases. Little information is available regarding the pathogenic mechanism of tubular damage by IF. We used the renal epithelial cell line LLC-PK1, which has many properties of the proximal tubule, in order to investigate the toxicity of IF and CP and of their reactive metabolites 4-hydroxy-IF (4-OH-IF), 4-hydroxy-CP (4-OH-CP), acrolein and chloroacetaldehyde (CAA). Protein content of monolayers, DNA and RNA synthesis were determined by standard techniques (thymidine and uridine incorporation). IF and CP had the lowest toxicities of all compounds tested. Both drugs inhibited thymidine incorporation by about 30% at a concentration of 300 mumol/l after 1 h incubation. 4-OH-IF and 4-OH-CP were significantly more toxic than the parent drugs. Thymidine incorporation, the most sensitive parameter, was reduced by about 70% by 300 mumol/l of either compound. In addition, 4-OH-CP reduced the total protein content of monolayers. 4-OH-IF did not effect protein content and RNA synthesis. Acrolein, the most toxic metabolite tested, reduced all three parameters significantly at concentrations of 50-75 mumol/l after 1 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Beneficial Effects of Bioactive Compounds in Mulberry Fruits against Cisplatin-Induced Nephrotoxicity.

Lee D, Yu J, Lee S, Hwang G, Kang K, Park J Int J Mol Sci. 2018; 19(4).

PMID: 29642519 PMC: 5979275. DOI: 10.3390/ijms19041117.


The effects and the toxicity increases caused by bicarbonate, chloride, and other water components during the UV/TiO degradation of oxazaphosphorine drugs.

Wei-Po Lai W, Chuang Y, Lin A Environ Sci Pollut Res Int. 2017; 24(17):14595-14604.

PMID: 28452030 DOI: 10.1007/s11356-017-9005-6.


Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.

Nishimura H, Enokida H, Nagano S, Yokouchi M, Hayami H, Komiya S J Artif Organs. 2013; 17(1):110-3.

PMID: 24091438 DOI: 10.1007/s10047-013-0733-1.


Protective role of Ipomoea obscura (L.) on cyclophosphamide-induced uro- and nephrotoxicities by modulating antioxidant status and pro-inflammatory cytokine levels.

Hamsa T, Kuttan G Inflammopharmacology. 2010; 19(3):155-67.

PMID: 20878549 DOI: 10.1007/s10787-010-0055-3.


Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide.

Abraham P, Rabi S Clin Exp Nephrol. 2009; 13(4):281-287.

PMID: 19266253 DOI: 10.1007/s10157-009-0160-z.


References
1.
Mohrmann M, Pauli A, Walkenhorst H, Schonfeld B, Brandis M . Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture. Ren Physiol Biochem. 1993; 16(6):285-98. DOI: 10.1159/000173775. View

2.
Biber J, Brown C, Murer H . Sodium-dependent transport of phosphate in LLC-PK1 cells. Biochim Biophys Acta. 1983; 735(3):325-30. DOI: 10.1016/0005-2736(83)90145-1. View

3.
Goren M, Wright R, Horowitz M, Pratt C . Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep. 1987; 71(2):127-30. View

4.
Dechant K, Brogden R, PILKINGTON T, Faulds D . Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991; 42(3):428-67. DOI: 10.2165/00003495-199142030-00006. View

5.
Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J . A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol. 1986; 18 Suppl 2:S25-8. DOI: 10.1007/BF00647446. View